NCT00828646已完成1 期
Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Adverse Events
研究概览
简要总结
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics, and pharmacodynamics following 14-day multiple oral doses BMS-708163 in healthy young male Japanese and healthy elderly male and female Japanese subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- •Body Mass Index (BMI) of 19 to 25 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2
- •Men, ages 20 to 45, and men and women [not of childbearing potential (i.e., who are postmenopausal or surgically sterile)], ages 65 or older. Women are considered surgically sterile only if they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy. Women are considered postmenopausal only if they have had amenorrhea for ≥12 consecutive months, or for women on hormone replacement therapy (HRT), if they have a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
排除标准
- •Women who are pregnant or breastfeeding
- •Women with a positive pregnancy test on enrollment or prior to administration of investigational product
- •Sexually active fertile men not using effective birth control if their partners are WOCBP
- •Any significant acute or chronic medical illness
- •Any current or recent? medical history of gastrointestinal disease that may affect evaluation of study treatment
- •History of recent major surgery or gastrointestinal surgery that may impact on evaluation or absorption of study drug
- •History of blood donation or blood transfusion within 4 weeks prior to the study treatment
- •Intolerance to oral medication or venous access
- •QTc interval (Bazett's correction) >500 ms at screening
- •Smoking more than 10 cigarettes per day
- •Recent (within 6 months) drug or alcohol abuse as defined in DSM IV
- •Any other sound medical, psychiatric and/or social reason as determined by the investigator
- •Subjects ≥ 65 yr are allowed to have age-related minimum or mild abnormalities in vital sign (i.e. blood pressure) or laboratory tests (i.e. blood sugar, serum cholesterol, or serum triglyceride) as far as they are not deemed signs or consequences of illness or organ dysfunction and a subject of medical treatment
- •Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
- •Positive urine screen for drugs of abuse
- •Positive blood screen for hepatitis C antibody, or HIV or hepatitis B antigen
- •Indicators of abnormal renal function at baseline: any urine protein
- •History of allergy to Gamma-Secretase Inhibitor or related compounds
- •History of any significant drug allergy
- •Prior exposure to BMS-708163
- •Exposure to any investigational drug or placebo within 4 weeks of study drug administration
- •Use of any prescription drugs or over-the-counter acid controllers within 4 weeks prior to study drug administration
- •Use of any other drugs, including over-the-counter medications and herbal preparations, within 2 weeks prior to study drug administration
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
研究组 & 干预措施
BMS-708163 - Panel 1
Experimental
(Age 20-45 years)
干预措施: BMS-708163 (Drug)
BMS-708163 - Panel 1
Experimental
(Age 20-45 years)
干预措施: Placebo (Drug)
BMS-708163 - Panel 2
Experimental
(Age 20-45 years)
干预措施: BMS-708163 (Drug)
BMS-708163 - Panel 2
Experimental
(Age 20-45 years)
干预措施: Placebo (Drug)
BMS-708163 - Panel 3
Experimental
(age 65 or above)
干预措施: BMS-708163 (Drug)
BMS-708163 - Panel 3
Experimental
(age 65 or above)
干预措施: Placebo (Drug)
BMS-708163 - Panel 4
Experimental
(age 65 or above)
干预措施: BMS-708163 (Drug)
BMS-708163 - Panel 4
Experimental
(age 65 or above)
干预措施: Placebo (Drug)
结局指标
主要结局
Adverse Events
时间窗: Within 30 days after the follow-up evaluation on Day 28
次要结局
- Plasma concentration(Day 21)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male SubjectsAlzheimer's DiseaseNCT01203384CERESPIR48
已完成
1 期
Phase I Multiple-Ascending Dose (Japan)Diabetes Mellitus, Type 2NCT00538174AstraZeneca36
已完成
1 期
Multiple-Dose Study of VGX-1027 in Healthy SubjectsHealthyNCT00760396VGX Pharmaceuticals, LLC40
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy SubjectsDepressionNCT00949767Bristol-Myers Squibb64
撤回
2 期
A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected SubjectsHIV InfectionsNCT00397566Bristol-Myers Squibb